Revance Therapeutics Inc
NASDAQ:RVNC
| Market Cap (Intraday) | 2.04B |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $27.79 |
| 50-Day MA | $27.45 |
| 200-Day MA | $26.59 |
Revance Therapeutics, Inc. Stock, NASDAQ:RVNC
1222 Demonbreun Street, Suite 1001, Nashville, Tennessee 37203
United States of America
Phone: +1.615.724.7755
Number of Employees: 193
Description
Revance Therapeutics, Inc. is a clinical stage biotechnology company. It engages in the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic applications. The firm focuses on production of daxibotulinumtoxinA, a botulinum toxin, for aesthetic and therapeutic indications, including facial wrinkles and muscle movement disorders. The company was founded by Jacob M. Waugh and L. Daniel Browne on August 10, 1999 and is headquartered in Nashville, TN.